TY - JOUR
T1 - Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis
AU - Thomadakis, Christos
AU - Gountas, Ilias
AU - Duffell, Erika
AU - Gountas, Konstantinos
AU - Bluemel, Benjamin
AU - Seyler, Thomas
AU - Pericoli, Filippo Maria
AU - Kászoni-Rückerl, Irene
AU - El-Khatib, Ziad
AU - Busch, Martin
AU - Schmutterer, Irene
AU - Vanwolleghem, Thomas
AU - Klamer, Sofieke
AU - Plettinckx, Els
AU - Mortgat, Laure
AU - Van Beckhoven, Dominique
AU - Varleva, Tonka
AU - Kosanovic Licina, Mirjana Lana
AU - Nemeth Blazic, Tatjana
AU - Nonković, Diana
AU - Theophanous, Fanitsa
AU - Nemecek, Vratislav
AU - Maly, Marek
AU - Christensen, Peer Brehm
AU - Cowan, Susan
AU - Rüütel, Kristi
AU - Brummer-Korvenkontio, Henrikki
AU - Brouard, Cécile
AU - Steffen, Gyde
AU - Krings, Amrei
AU - Dudareva, Sandra
AU - Zimmermann, Ruth
AU - Nikolopoulou, Georgia
AU - Molnár, Zsuzsanna
AU - Kozma, Emese
AU - Gottfredsson, Magnús
AU - Murphy, Niamh
AU - Kondili, Loreta A.
AU - Tosti, Maria Elena
AU - Ciccaglione, Anna Rita
AU - Suligoi, Barbara
AU - Nikiforova, Raina
AU - Putnina, Renate
AU - Jancoriene, Ligita
AU - Seguin-Devaux, Carole
AU - Melillo, Tanya
AU - Boyd, Anders
AU - van der Valk, Marc
AU - Op de Coul, Eline
AU - Whittaker, Robert
AU - Kløvstad, Hilde
AU - Stępień, Małgorzata
AU - Rosińska, Magdalena
AU - Valente, Cristina
AU - Marinho, Rui Tato
AU - Popovici, Odette
AU - Avdičová, Mária
AU - Kerlik, Jana
AU - Klavs, Irena
AU - Maticic, Mojca
AU - Diaz, Asuncion
AU - del Amo, Julia
AU - Lundberg Ederth, Josefine
AU - Axelsson, Maria
AU - Nikolopoulos, Georgios
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2024/1
Y1 - 2024/1
N2 - Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.
AB - Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.
KW - Chronic hepatitis
KW - Elimination
KW - Europe
KW - HCV
KW - Hepatitis C
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85180548657&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38188273
U2 - 10.1016/j.lanepe.2023.100792
DO - 10.1016/j.lanepe.2023.100792
M3 - Article
C2 - 38188273
AN - SCOPUS:85180548657
SN - 2666-7762
VL - 36
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 100792
ER -